Press ReleaseIB Communicationsbracco@ibcomms.agency Bracco Enters Cell Therapy Manufacturing with Cell Selection and Activation TechnologiesTechnology based on Bracco’s clinically validated ...

Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...

The agreement grants Repertoire an upfront payment of $85m, with the possibility of up to $1.84bn in additional milestone payments.

InSysBio, one of the world's pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with BeOne Medicines, a global oncology company.

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the ...

In this free webinar, gain insight into the principles of mRNA and LNP technology and their unique advantages for in vivo CAR T-cell development. Attendees will learn how mRNA synthesis, LNP ...

A cutting-edge therapy using base-edited immune cells is offering a major breakthrough for patients with one of the toughest forms of blood cancer, T-cell acute lymphoblastic leukaemia. By precisely ...

Data support the development of Tolerance Bio’s thymic cells and pharmacological approaches for thymus regeneration in aging-related diseases, including cancer PHILADELPHIA--(BUSINESS WIRE)--Tolerance ...

Thymic selection is crucial for forming a pool of T-cells that can efficiently discriminate self from non-self using their T-cell receptors (TCRs) to develop adaptive immunity. In the present study we ...